Hbvtech, L.l.c
Germantown, MD
Company facts
- Self-certified in SAM.gov
- Entity structure
- Sole Proprietorship
- SAM.gov registration date
- Physical address
- 13901 Lullaby Rd, Germantown, MD 20874, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $606,178 |
| FY2024 | $0 |
| FY2023 | $50,000 |
Contract awards
Grant awards
Similar vendors
About the company
Hbvtech, L.l.c is a minority-owned small disadvantaged business located in Germantown, Maryland, specializing in advanced medical research focused on developing innovative antiviral treatments and gene therapies targeting hepatitis B virus (HBV) infections. As a small business registered in SAM.gov since 2013, the company operates as a limited liability company with a focus on developing cutting-edge medical solutions for chronic infectious diseases. Hbvtech has demonstrated significant expertise in researching and developing potential therapeutic interventions for HBV, leveraging advanced gene therapy techniques and molecular biology approaches to address complex medical challenges.
Through federal contract awards, Hbvtech has primarily engaged with the National Institute of Allergy and Infectious Diseases (NIAID) on specialized research projects. The company has received firm-fixed price contracts under the Small Business Innovation Research (SBIR) program, specifically focusing on evaluating HBVZ10-based therapies for covalently closed circular DNA (cccDNA) clearance. These contracts, valued at approximately $2.6 million and $1.55 million, involve developing antiviral drugs and investigating innovative strategies for curing chronic HBV infections. The contracts were set aside for small businesses and involved detailed virological research aimed at understanding and potentially eliminating HBV infection mechanisms.
Hbvtech has secured multiple federal grant awards from agencies including the National Institute of Allergy and Infectious Diseases, Defense Health Agency, and Department of the Army Medical Command. These project grants, totaling approximately $5.26 million, support research on developing novel HBV treatment approaches, including gene therapy strategies for curing chronic HBV infection. The grants focus on exploring unconventional methods for eliminating HBV covalently closed circular DNA, developing AAV vector-based gene therapies, and establishing sustained anti-HBs antibody production. Research activities under these grants aim to transform muscle cells into antibody production factories, block HBV reinfection, and ultimately provide a potential cure for chronic HBV infections, addressing a significant global health challenge.
Quick answers
Is Hbvtech, L.l.c registered in SAM.gov?
Yes. Hbvtech, L.l.c's SAM.gov registration is active through December 21, 2026.
What is Hbvtech, L.l.c's CAGE code?
Hbvtech, L.l.c's CAGE code is 6WC76, and its Unique Entity ID (UEI) is WEXNYHY4EZB5.
How much has Hbvtech, L.l.c received in federal contracts?
Federal contracts obligated $606,178 to Hbvtech, L.l.c in fiscal year 2025 and $656,178 in fiscal years 2023 through 2027.
What is Hbvtech, L.l.c's most recent federal award?
Hbvtech, L.l.c's most recent federal grant award is A development strategy to obtain IND approval of HBVZ10, a new HBV cure therapy candidate - HBV cccdna persistence is… (R34AI194337), from National Institute of Allergy and Infectious Diseases (NIH), on September 1, 2025.
On GovTribe
See Hbvtech, L.l.c's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors